Foundation Medicine at the 8th Annual Liquid Biopsy for Precision Oncology Summit

Join us for two exciting networking and learning opportunities as part of our lead sponsorship at the meeting:

1. Wednesday, February 28th, 9 am – 12 pm:
   Foundation Medicine will be hosting a workshop to discuss “What's Next In the Future of Liquid Biopsy,” featuring voices from the industry in partnership with Foundation Medicine.

• Discussion on strategic trial design using ctDNA monitoring in drug development
• Breakout groups to talk with your peers and Foundation Medicine experts about the opportunities and challenges with liquid biopsy testing in drug development today
• Discussion on how to bring liquid biopsy to global markets through trials and commercialization, including our IVDR experience
• This is an invitation only event, if interested please fill out the form below.

2. Thursday, February 29th, 8:30 am – 9:00 am:
   Amanda Young, Senior Director, Lifecycle Product Development, will be presenting “Introducing an Improved ctDNA Tumor Fraction Method to Add Value in Translational Research, Clinical Trials & CDx Development”

• Discussion on the value of ctDNA monitoring for research and clinical trial programs, including both early- and late-stage disease for MRD and treatment response
• Confidence in negative results from a liquid biopsy test, now possible for wild-type biomarkers in trial enrollment
• New data on the value of ctDNA tumor fraction in lung, breast, bladder, and kidney cancers
• Learn more about our Discovery & Translational Research capabilities here